Results of the Planned Interim Analysis and Update on Topline Read-out for the Essential3 Program: The Independent Data Monitoring Committee (IDMC) overseeing the interim analysis of Study 1 of ...
21d
Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback